253 related articles for article (PubMed ID: 23744091)
1. Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131).
Mimoto F; Katada H; Kadono S; Igawa T; Kuramochi T; Muraoka M; Wada Y; Haraya K; Miyazaki T; Hattori K
Protein Eng Des Sel; 2013 Oct; 26(10):589-98. PubMed ID: 23744091
[TBL] [Abstract][Full Text] [Related]
2. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
Zhang D; Goldberg MV; Chiu ML
J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
[TBL] [Abstract][Full Text] [Related]
3. Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa.
Ahmed AA; Keremane SR; Vielmetter J; Bjorkman PJ
J Struct Biol; 2016 Apr; 194(1):78-89. PubMed ID: 26850169
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
[TBL] [Abstract][Full Text] [Related]
5. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
6. Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.
Mimoto F; Igawa T; Kuramochi T; Katada H; Kadono S; Kamikawa T; Shida-Kawazoe M; Hattori K
MAbs; 2013; 5(2):229-36. PubMed ID: 23406628
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Fcgamma receptor IIa (cd32) gene polymorphism and anti-malarial IgG subclass antibodies to asexual blood-stage antigen of Plasmodium falciparum in an unstable malaria endemic area of Iran.
Zakeri S; Mashhadi R; Mehrizi AA; Djadid ND
Exp Parasitol; 2013 May; 134(1):115-21. PubMed ID: 23458236
[TBL] [Abstract][Full Text] [Related]
8. Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity.
Jung ST; Kelton W; Kang TH; Ng DT; Andersen JT; Sandlie I; Sarkar CA; Georgiou G
ACS Chem Biol; 2013 Feb; 8(2):368-75. PubMed ID: 23030766
[TBL] [Abstract][Full Text] [Related]
9. A general Fc engineering platform for the next generation of antibody therapeutics.
Chen D; Zhao Y; Li M; Shang H; Li N; Li F; Wang W; Wang Y; Jin R; Liu S; Li X; Gao S; Tian Y; Li R; Li H; Zhang Y; Du M; Cao Y; Zhang Y; Li X; Huang Y; Hu LA; Li F; Zhang H
Theranostics; 2021; 11(4):1901-1917. PubMed ID: 33408788
[No Abstract] [Full Text] [Related]
10. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.
Liu Z; Gunasekaran K; Wang W; Razinkov V; Sekirov L; Leng E; Sweet H; Foltz I; Howard M; Rousseau AM; Kozlosky C; Fanslow W; Yan W
J Biol Chem; 2014 Feb; 289(6):3571-90. PubMed ID: 24311787
[TBL] [Abstract][Full Text] [Related]
11. Fc Binding by FcγRIIa Is Essential for Cellular Activation by the Anti-FcγRIIa mAbs 8.26 and 8.2.
Wines BD; Trist HM; Esparon S; Impey RE; Mackay GA; Andrews RK; Soares da Costa TP; Pietersz GA; Baker RI; Hogarth PM
Front Immunol; 2021; 12():666813. PubMed ID: 34759915
[TBL] [Abstract][Full Text] [Related]
12. Differential recruitment of activating and inhibitory Fc gamma RII during phagocytosis.
Syam S; Mero P; Pham T; McIntosh CA; Bruhns P; Booth JW
J Immunol; 2010 Mar; 184(6):2966-73. PubMed ID: 20154205
[TBL] [Abstract][Full Text] [Related]
13. Structural characterization of a human Fc fragment engineered for lack of effector functions.
Oganesyan V; Gao C; Shirinian L; Wu H; Dall'Acqua WF
Acta Crystallogr D Biol Crystallogr; 2008 Jun; 64(Pt 6):700-4. PubMed ID: 18560159
[TBL] [Abstract][Full Text] [Related]
14. Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies.
Yu X; Baruah K; Harvey DJ; Vasiljevic S; Alonzi DS; Song BD; Higgins MK; Bowden TA; Scanlan CN; Crispin M
J Am Chem Soc; 2013 Jul; 135(26):9723-32. PubMed ID: 23745692
[TBL] [Abstract][Full Text] [Related]
15. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
16. Immunity against a therapeutic xenoprotein/Fc construct delivered by gene transfer is reduced through binding to the inhibitory receptor FcγRIIb.
Liang Y; Qiu H; Glinka Y; Lazarus AH; Ni H; Prud'homme GJ; Wang Q
J Gene Med; 2011 Sep; 13(9):470-7. PubMed ID: 21786368
[TBL] [Abstract][Full Text] [Related]
17. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.
Schlothauer T; Herter S; Koller CF; Grau-Richards S; Steinhart V; Spick C; Kubbies M; Klein C; Umaña P; Mössner E
Protein Eng Des Sel; 2016 Oct; 29(10):457-466. PubMed ID: 27578889
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes.
Ramsland PA; Farrugia W; Bradford TM; Sardjono CT; Esparon S; Trist HM; Powell MS; Tan PS; Cendron AC; Wines BD; Scott AM; Hogarth PM
J Immunol; 2011 Sep; 187(6):3208-17. PubMed ID: 21856937
[TBL] [Abstract][Full Text] [Related]
19. Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to FcγRIIb.
Cemerski S; Chu SY; Moore GL; Muchhal US; Desjarlais JR; Szymkowski DE
Immunol Lett; 2012 Mar; 143(1):34-43. PubMed ID: 22305932
[TBL] [Abstract][Full Text] [Related]
20. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody.
Chu SY; Horton HM; Pong E; Leung IW; Chen H; Nguyen DH; Bautista C; Muchhal US; Bernett MJ; Moore GL; Szymkowski DE; Desjarlais JR
J Allergy Clin Immunol; 2012 Apr; 129(4):1102-15. PubMed ID: 22257644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
